(PharmaNewsWire.Com, November 16, 2021 ) Growth in the infertility treatment market is primarily driven by factors such as the declining fertility rate, rising number of fertility clinics worldwide, technological advancements, and increasing public-private investments, funds, and grants. However, the high procedural costs of assisted reproductive technology procedures in developed markets and unsupportive government regulations for certain infertility treatment options are expected to limit market growth to a certain extent.
The coronavirus pandemic is currently presenting various challenges to clinical healthcare providers and patients across the globe. Logistical issues, managing patients with the disease, prioritizing patients with comorbidities and pre-existing conditions, and protecting public hospital frontline workers from exposure to the COVID-19 infection are the major challenges faced by healthcare systems across the globe.
During the COVID-19 pandemic, a 90% drop was observed in the number of people undergoing IVF cycles. The spread of COVID-19 has not only impacted fertility clinics owing to the cancellation of IVF treatments but has also impacted fertility decisions among couples who were opting for IVF treatment before the pandemic.
Global fertility rates are projected to decline to 2.4 children per woman by 2030 and 2.2 children per woman by 2050. This declining fertility rate has led to a significant increase in the demand for infertility treatment products that determine the fertility window in males and females.
The cost of IVF treatment varies from country to country due to the lack of reimbursement policies. A lack of insurance coverage and the poor reimbursement scenario in some parts of the world are limiting the growth of this market.
The infertility treatment market in Asia and other emerging countries is characterized by the growing focus on healthcare infrastructural improvements. Additionally, the medical tourism industry in emerging countries is thriving owing to a number of factors.
To leverage the significant growth opportunities in emerging countries, players are increasingly focusing on undertaking strategic developments agreements/partnerships with regional/domestic players, geographical expansions, and acquisitions.to increase their presence in these markets and tap a large number of customers. In addition, government initiatives to increase the accessibility of infertility treatments, and the growing number of fertility centers are also fuelling the growth of infertility treatment procedures in emerging countries.
Authorities such as the International Federation of Fertility Societies (IFFS), European Society of Human Reproduction and Embryology (ESHRE), Indian Council of Medical Research (ICMR), Ethics Committee of American Society for Reproductive Medicine (ASRM), and Human Fertilization and Embryology Authority (HFEA) have implemented stringent regulations for infertility treatment.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: